Form 4: QTTB director receives options; vest by Oct 2026
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lundberg Sven Ante
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 53,521 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 53,521 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did QTTB disclose in this Form 4?
A director received 53,521 stock options with an exercise price of $2.80 per share on 10/23/2025.
When do the QTTB director’s options vest?
They vest in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service.
What is the expiration date of the options?
The options expire on 10/22/2035.
How many derivative securities does the director hold after this grant?
The director beneficially owns 53,521 derivative securities following the reported transaction.
What is the exercise price of the granted options?
The exercise price is $2.80 per share.
Is this a direct or indirect holding?
The filing lists ownership as Direct (D).